Literature DB >> 1326210

Preinductive cervical ripening with prostaglandin E2 in women with one previous cesarean section.

M Norman1, G Ekman.   

Abstract

Thirty term pregnant women with one previous cesarean section and with unripe cervices were given 0.5 mg prostaglandin E2 in gel strictly intracervically for cervical ripening and labor induction. Fifteen out of these 30 women (50%) were vaginally delivered within 24 hours. The cervical ripening/labor induction was considered a failure in two women. In one woman, an episode of hypercontractility was registered. After tocolytic therapy the uterine activity was normalised and the woman had a normal vaginal delivery. The frequency of cesarean sections was 8/30 (27%). At the operations no insufficiencies in the uterine scars were noted. Conclusively, strict intracervical application of 0.5 mg prostaglandin E2 in gel can be used for cervical ripening and labor induction also in women with one previous cesarean section.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326210     DOI: 10.3109/00016349209021072

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  4 in total

Review 1.  Evidence based case report: use of prostaglandins to induce labour in women with a caesarean section scar.

Authors:  S Vause; M Macintosh
Journal:  BMJ       Date:  1999-04-17

Review 2.  A risk-benefit assessment of oxytocics in obstetric practice.

Authors:  M Winkler; W Rath
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

3.  Evaluating trial of scar in patients with a history of caesarean section.

Authors:  Aliya Islam; Ambreen Ehsan; Saadia Arif; Javeria Murtaza; Ayesha Hanif
Journal:  N Am J Med Sci       Date:  2011-04

4.  Cervical ripening with low-dose prostaglandins in planned vaginal birth after cesarean.

Authors:  Thomas Schmitz; Anne-Gaelle Pourcelot; Constance Moutafoff; Valérie Biran; Olivier Sibony; Jean-François Oury
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.